Rivaroxaban found beneficial for patients with ACS

Rivaroxaban found beneficial for patients with ACS

Rivaroxaban found beneficial for patients with ACS: Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Jean-Pierre Bassand, Deepak L Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A A Fox, Shinya Goto, Sabina A Murphy, Alexei N Plotnikov, David Schneider, Xiang Sun, Freek W A Verheugt and C Michael Gibson the ATLAS ACS 2–TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome 2–Thrombolysis in Myocardial Infarction 51) Investigators [1] evaluated the role of factor Xa inhibitor rivaroxaban in acute coronary syndrome (ACS).

It was a double blind placebo controlled trial involving more than fifteen thousand and five hundred patients. Rivaroxaban was used in doses of 2.5 mg or 5 mg twice daily with a mean follow up of thirteen months. Composite of death from cardiovascular causes, myocardial infarction, or stroke was the primary efficacy endpoint. They concluded that rivaroxaban reduced the risk of composite endpoint in ACS, but increased the risk of major bleeding and intracranial hemorrhage, though not the risk of fatal bleeding.

Reference

1. Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Jean-Pierre Bassand, Deepak L Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A A Fox, Shinya Goto, Sabina A Murphy, Alexei N Plotnikov, David Schneider, Xiang Sun, Freek W A Verheugt, C Michael Gibson, ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366(1):9-19.